A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Verastem, Inc.
AstraZeneca
Seagen Inc.
Seagen Inc.
Pfizer
M.D. Anderson Cancer Center
Jiangsu Cancer Institute & Hospital
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Genmab
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Actuate Therapeutics Inc.
NRG Oncology
Revolution Medicines, Inc.
Bristol-Myers Squibb
AstraZeneca
Changhai Hospital
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Hoosier Cancer Research Network
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
AstraZeneca
Centre Oscar Lambret
Pfizer
University of California, Irvine
Qilu Pharmaceutical Co., Ltd.
Neonc Technologies, Inc.
UNC Lineberger Comprehensive Cancer Center
AstraZeneca
National Cancer Institute (NCI)
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Eli Lilly and Company
Abramson Cancer Center at Penn Medicine
OHSU Knight Cancer Institute
Shanghai Zhongshan Hospital
Jiangsu Cancer Institute & Hospital
Children's Oncology Group
AHS Cancer Control Alberta
Shanghai Zhongshan Hospital
Second Affiliated Hospital, School of Medicine, Zhejiang University
Blueprint Medicines Corporation
Massachusetts General Hospital
Sichuan Cancer Hospital and Research Institute
National Cancer Institute (NCI)
Massachusetts General Hospital
Incyte Corporation
Tesaro, Inc.
Maastricht University Medical Center
Eli Lilly and Company